Examining the Effectiveness of Electronic Patient-Reported Outcomes in People With Cancer: Systematic Review and Meta-Analysis.

meta-analysis neoplasms patient-reported outcome measure quality of life randomized controlled trial systematic review telemedicine

Journal

Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882

Informations de publication

Date de publication:
31 Jul 2024
Historique:
received: 17 05 2023
accepted: 10 04 2024
revised: 07 02 2024
medline: 31 7 2024
pubmed: 31 7 2024
entrez: 31 7 2024
Statut: epublish

Résumé

Electronic patient-reported outcomes (ePROs) are commonly used in oncology clinical practice and have shown benefits for patients and health resource use. The aim of this study was to compare the isolated effect of administering ePROs to patients with cancer versus a control condition. The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were followed. Randomized controlled trials evaluating ePRO interventions that aimed to improve health-related outcomes among patients with cancer were included. The primary outcome was health-related quality of life (HRQOL), and the secondary outcomes were symptoms, hospital admissions, unplanned visits, chemotherapy completion, survival, and satisfaction with care. The effect sizes of ePROs on health-related outcomes were analyzed as standardized mean differences (SMDs) with 95% CIs using a random effects model. The search identified 10,965 papers, of which 19 (0.17%) from 15 studies were included. The meta-analysis showed an improvement in HRQOL at 3 months, measured by the Functional Assessment of Cancer Therapy-General (SMD 0.28, 95% CI -1.22 to 1.78), and at 6 months, assessed using various HRQOL measures (SMD 0.07, 95% CI -1.24 to 1.39). The results should be interpreted with caution, given the wide 95% CIs. Of the 15 studies, 9 (60%) reported a positive signal on HRQOL, with two-thirds of the studies (n=6, 67%) including tailored patient advice and two-thirds (n=6, 67%) using clinician alert systems. The meta-analysis showed a potential improvement in HRQOL at 6 months and in Functional Assessment of Cancer Therapy-General scores at 3 months for studies that included tailored advice and clinician alerts, suggesting that these elements may improve ePRO effectiveness. The findings will provide guidance for future use and help health care professionals choose the most suitable ePRO features for their patients. PROSPERO CRD42020175007; https://tinyurl.com/5cwmy3j6.

Sections du résumé

BACKGROUND BACKGROUND
Electronic patient-reported outcomes (ePROs) are commonly used in oncology clinical practice and have shown benefits for patients and health resource use.
OBJECTIVE OBJECTIVE
The aim of this study was to compare the isolated effect of administering ePROs to patients with cancer versus a control condition.
METHODS METHODS
The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were followed. Randomized controlled trials evaluating ePRO interventions that aimed to improve health-related outcomes among patients with cancer were included. The primary outcome was health-related quality of life (HRQOL), and the secondary outcomes were symptoms, hospital admissions, unplanned visits, chemotherapy completion, survival, and satisfaction with care. The effect sizes of ePROs on health-related outcomes were analyzed as standardized mean differences (SMDs) with 95% CIs using a random effects model.
RESULTS RESULTS
The search identified 10,965 papers, of which 19 (0.17%) from 15 studies were included. The meta-analysis showed an improvement in HRQOL at 3 months, measured by the Functional Assessment of Cancer Therapy-General (SMD 0.28, 95% CI -1.22 to 1.78), and at 6 months, assessed using various HRQOL measures (SMD 0.07, 95% CI -1.24 to 1.39). The results should be interpreted with caution, given the wide 95% CIs. Of the 15 studies, 9 (60%) reported a positive signal on HRQOL, with two-thirds of the studies (n=6, 67%) including tailored patient advice and two-thirds (n=6, 67%) using clinician alert systems.
CONCLUSIONS CONCLUSIONS
The meta-analysis showed a potential improvement in HRQOL at 6 months and in Functional Assessment of Cancer Therapy-General scores at 3 months for studies that included tailored advice and clinician alerts, suggesting that these elements may improve ePRO effectiveness. The findings will provide guidance for future use and help health care professionals choose the most suitable ePRO features for their patients.
TRIAL REGISTRATION BACKGROUND
PROSPERO CRD42020175007; https://tinyurl.com/5cwmy3j6.

Identifiants

pubmed: 39083791
pii: v26i1e49089
doi: 10.2196/49089
doi:

Types de publication

Journal Article Systematic Review Meta-Analysis Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e49089

Informations de copyright

©Melissa Betty Perry, Sally Taylor, Binish Khatoon, Amy Vercell, Corinne Faivre-Finn, Galina Velikova, Antonia Marsden, Calvin Heal, Janelle Yorke. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 31.07.2024.

Auteurs

Melissa Betty Perry (MB)

Christie Patient Centred Research, The Christie NHS Foundation Trust, Manchester, United Kingdom.

Sally Taylor (S)

Christie Patient Centred Research, The Christie NHS Foundation Trust, Manchester, United Kingdom.
Division of Nursing Midwifery and Social Work, School of Health Sciences, Faculty of Biology, Medicine & Health, The University of Manchester, Manchester, United Kingdom.

Binish Khatoon (B)

Christie Patient Centred Research, The Christie NHS Foundation Trust, Manchester, United Kingdom.
Division of Nursing Midwifery and Social Work, School of Health Sciences, Faculty of Biology, Medicine & Health, The University of Manchester, Manchester, United Kingdom.

Amy Vercell (A)

Christie Patient Centred Research, The Christie NHS Foundation Trust, Manchester, United Kingdom.

Corinne Faivre-Finn (C)

Division of Cancer Science, The University of Manchester, Manchester, United Kingdom.
Clinical Oncology Department, The Christie NHS Foundation Trust, Manchester, United Kingdom.

Galina Velikova (G)

Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom.
St James's Institute of Oncology, St James's University Hospital, Leeds, United Kingdom.

Antonia Marsden (A)

Division of Population Health, Health Services Research & Primary Care, The University of Manchester, Manchester, United Kingdom.

Calvin Heal (C)

Division of Population Health, Health Services Research & Primary Care, The University of Manchester, Manchester, United Kingdom.

Janelle Yorke (J)

Christie Patient Centred Research, The Christie NHS Foundation Trust, Manchester, United Kingdom.
Division of Nursing Midwifery and Social Work, School of Health Sciences, Faculty of Biology, Medicine & Health, The University of Manchester, Manchester, United Kingdom.
School of Nursing, The Hong Kong Polytechnic University, Kowloon, China (Hong Kong).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH